These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 34461927)

  • 21. Detection of wild-type EGFR amplification and EGFRvIII mutation in CSF-derived extracellular vesicles of glioblastoma patients.
    Figueroa JM; Skog J; Akers J; Li H; Komotar R; Jensen R; Ringel F; Yang I; Kalkanis S; Thompson R; LoGuidice L; Berghoff E; Parsa A; Liau L; Curry W; Cahill D; Bettegowda C; Lang FF; Chiocca EA; Henson J; Kim R; Breakefield X; Chen C; Messer K; Hochberg F; Carter BS
    Neuro Oncol; 2017 Oct; 19(11):1494-1502. PubMed ID: 28453784
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Analysis of complex relationships between age, p53, epidermal growth factor receptor, and survival in glioblastoma patients.
    Simmons ML; Lamborn KR; Takahashi M; Chen P; Israel MA; Berger MS; Godfrey T; Nigro J; Prados M; Chang S; Barker FG; Aldape K
    Cancer Res; 2001 Feb; 61(3):1122-8. PubMed ID: 11221842
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Quantitative assessment of intragenic receptor tyrosine kinase deletions in primary glioblastomas: their prevalence and molecular correlates.
    Kastenhuber ER; Huse JT; Berman SH; Pedraza A; Zhang J; Suehara Y; Viale A; Cavatore M; Heguy A; Szerlip N; Ladanyi M; Brennan CW
    Acta Neuropathol; 2014 May; 127(5):747-59. PubMed ID: 24292886
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Human TERT promoter mutation enables survival advantage from MGMT promoter methylation in IDH1 wild-type primary glioblastoma treated by standard chemoradiotherapy.
    Nguyen HN; Lie A; Li T; Chowdhury R; Liu F; Ozer B; Wei B; Green RM; Ellingson BM; Wang HJ; Elashoff R; Liau LM; Yong WH; Nghiemphu PL; Cloughesy T; Lai A
    Neuro Oncol; 2017 Mar; 19(3):394-404. PubMed ID: 27571882
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Molecular characterization of EGFR and EGFRvIII signaling networks in human glioblastoma tumor xenografts.
    Johnson H; Del Rosario AM; Bryson BD; Schroeder MA; Sarkaria JN; White FM
    Mol Cell Proteomics; 2012 Dec; 11(12):1724-40. PubMed ID: 22964225
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prognostic Molecular and Imaging Biomarkers in Primary Glioblastoma.
    Bosnyák E; Michelhaugh SK; Klinger NV; Kamson DO; Barger GR; Mittal S; Juhász C
    Clin Nucl Med; 2017 May; 42(5):341-347. PubMed ID: 28195901
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Epidermal Growth Factor Receptor Variant III (EGFRvIII) Positivity in
    Felsberg J; Hentschel B; Kaulich K; Gramatzki D; Zacher A; Malzkorn B; Kamp M; Sabel M; Simon M; Westphal M; Schackert G; Tonn JC; Pietsch T; von Deimling A; Loeffler M; Reifenberger G; Weller M;
    Clin Cancer Res; 2017 Nov; 23(22):6846-6855. PubMed ID: 28855349
    [No Abstract]   [Full Text] [Related]  

  • 28. Expression and prognostic significance of TCTN1 in human glioblastoma.
    Meng D; Chen Y; Zhao Y; Wang J; Yun D; Yang S; Chen J; Chen H; Lu D
    J Transl Med; 2014 Oct; 12():288. PubMed ID: 25304031
    [TBL] [Abstract][Full Text] [Related]  

  • 29. TERT promoter mutation status is necessary and sufficient to diagnose IDH-wildtype diffuse astrocytic glioma with molecular features of glioblastoma.
    Fujimoto K; Arita H; Satomi K; Yamasaki K; Matsushita Y; Nakamura T; Miyakita Y; Umehara T; Kobayashi K; Tamura K; Tanaka S; Higuchi F; Okita Y; Kanemura Y; Fukai J; Sakamoto D; Uda T; Machida R; Kuchiba A; Maehara T; Nagane M; Nishikawa R; Suzuki H; Shibuya M; Komori T; Narita Y; Ichimura K
    Acta Neuropathol; 2021 Aug; 142(2):323-338. PubMed ID: 34148105
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The impact of MGMT methylation and IDH-1 mutation on long-term outcome for glioblastoma treated with chemoradiotherapy.
    Millward CP; Brodbelt AR; Haylock B; Zakaria R; Baborie A; Crooks D; Husband D; Shenoy A; Wong H; Jenkinson MD
    Acta Neurochir (Wien); 2016 Oct; 158(10):1943-53. PubMed ID: 27526690
    [TBL] [Abstract][Full Text] [Related]  

  • 31. IDH1 mutation of gliomas with long-term survival analysis.
    Myung JK; Cho HJ; Park CK; Kim SK; Phi JH; Park SH
    Oncol Rep; 2012 Nov; 28(5):1639-44. PubMed ID: 22922798
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Spectrum of EGFR aberrations and potential clinical implications: insights from integrative pan-cancer analysis.
    Liu H; Zhang B; Sun Z
    Cancer Commun (Lond); 2020 Jan; 40(1):43-59. PubMed ID: 32067422
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Epidermal growth factor receptor gene amplification as a prognostic marker in glioblastoma multiforme: results of a meta-analysis.
    Huncharek M; Kupelnick B
    Oncol Res; 2000; 12(2):107-12. PubMed ID: 11132923
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Identification of New Genetic Clusters in Glioblastoma Multiforme:
    Navarro L; San-Miguel T; Megías J; Santonja N; Calabuig S; Muñoz-Hidalgo L; Roldán P; Cerdá-Nicolás M; López-Ginés C
    Cells; 2020 Nov; 9(11):. PubMed ID: 33172155
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Identification of prognostic gene signatures of glioblastoma: a study based on TCGA data analysis.
    Kim YW; Koul D; Kim SH; Lucio-Eterovic AK; Freire PR; Yao J; Wang J; Almeida JS; Aldape K; Yung WK
    Neuro Oncol; 2013 Jul; 15(7):829-39. PubMed ID: 23502430
    [TBL] [Abstract][Full Text] [Related]  

  • 36. EGFR amplification and classical subtype are associated with a poor response to bevacizumab in recurrent glioblastoma.
    Hovinga KE; McCrea HJ; Brennan C; Huse J; Zheng J; Esquenazi Y; Panageas KS; Tabar V
    J Neurooncol; 2019 Apr; 142(2):337-345. PubMed ID: 30680510
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prognostic significance of immunohistochemical staining for myoferlin in clear cell renal cell carcinoma and its association with epidermal growth factor receptor expression.
    Jung M; Lee C; Park JH; Moon KC
    Urol Oncol; 2019 Nov; 37(11):812.e9-812.e16. PubMed ID: 31421995
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Molecular predictors of progression-free and overall survival in patients with newly diagnosed glioblastoma: a prospective translational study of the German Glioma Network.
    Weller M; Felsberg J; Hartmann C; Berger H; Steinbach JP; Schramm J; Westphal M; Schackert G; Simon M; Tonn JC; Heese O; Krex D; Nikkhah G; Pietsch T; Wiestler O; Reifenberger G; von Deimling A; Loeffler M
    J Clin Oncol; 2009 Dec; 27(34):5743-50. PubMed ID: 19805672
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prognostic significance of O6-methylguanine-DNA-methyltransferase (MGMT) promoter methylation and isocitrate dehydrogenase-1 (IDH-1) mutation in glioblastoma multiforme patients: A single-center experience in the Middle East region.
    Ayoub Z; Geara F; Najjar M; Comair Y; Khoueiry-Zgheib N; Khoueiry P; Mahfouz R; Boulos FI; Kamar FG; Andraos T; Saadeh F; Kreidieh F; Abboud M; Skaf G; Assi HI
    Clin Neurol Neurosurg; 2019 Jul; 182():92-97. PubMed ID: 31108342
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Nuclear transport of phosphorylated LanCL2 promotes invadopodia formation and tumor progression of glioblastoma by activating STAT3/Cortactin signaling.
    Zhao HF; Liu YS; Wang J; Wu CP; Zhou XM; Cai LR; Liu J; Liu XJ; Xu YW; Li WP; Huang GD
    J Adv Res; 2024 Mar; ():. PubMed ID: 38492734
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.